Filing Flows › Actinium Pharmaceuticals (ATNM) › Stock forecast & fair value
Actinium Pharmaceuticals (ATNM) stock forecast and price target
Actinium Pharmaceuticals (ATNM) trades at $1.43. 4 analysts' median price target is $4.00 (+180%), from $3.00 to $5.00.
Actinium Pharmaceuticals' latest quarter
Actinium Pharmaceuticals, Q2 2026: revenue $35.0M, operating margin 78.8%, net earnings $27.9M, operating cash flow −$5.2M. The chart follows the revenue to costs, profit and cash.
Questions
What is the price target for ATNM stock?
The median of 4 analysts' 12-month targets is $4.00, +180% from $1.43; the range is $3.00 to $5.00. The average rating is none.
Does Actinium Pharmaceuticals usually beat earnings estimates?
It beat the consensus EPS estimate in 75% of the quarters on record.
Is ATNM stock a buy?
Filing Flows does not give advice. It shows what analysts expect, what each valuation method implies and the figures behind them, read from SEC filings, so you can judge for yourself.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.